Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7870590, 7 pages
http://dx.doi.org/10.1155/2016/7870590
Research Article

Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma

1Department of Hematology, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia
2Department of Pathology, School of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
3Department of Laboratory Medicine, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia
4Department of Cytology, Rijeka University Hospital Centre, Krešimirova 42, 51000 Rijeka, Croatia

Received 25 September 2015; Revised 26 November 2015; Accepted 8 December 2015

Academic Editor: Nicola Amodio

Copyright © 2016 Toni Valković et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Palumbo and K. Anderson, “Multiple myeloma,” The New England Journal of Medicine, vol. 364, no. 11, pp. 1046–1060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Balakumaran, P. G. Robey, N. Fedarko, and O. Landgren, “Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis,” Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 465–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Adams, “The proteasome: a suitable antineoplastic target,” Nature Reviews Cancer, vol. 4, no. 5, pp. 349–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Quach, D. Ritchie, A. K. Stewart et al., “Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma,” Leukemia, vol. 24, no. 1, pp. 22–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Kumar, T. E. Witzig, M. Timm et al., “Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression,” Blood, vol. 104, no. 4, pp. 1159–1165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Giuliani, S. Colla, and V. Rizzoli, “Angiogenic switch in multiple myeloma,” Hematology, vol. 9, no. 5-6, pp. 377–381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Möller, T. Strömberg, M. Juremalm, K. Nilsson, and G. Nilsson, “Expression and function of chemokine receptors in human multiple myeloma,” Leukemia, vol. 17, no. 1, pp. 203–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Aggarwal, I. M. Ghobrial, and G. D. Roodman, “Chemokines in multiple myeloma,” Experimental Hematology, vol. 34, no. 10, pp. 1289–1295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Baggiolini and P. Loetscher, “Chemokines in inflammation and immunity,” Immunology Today, vol. 21, no. 9, pp. 418–420, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Vande Broek, K. Asosingh, K. Vanderkerken, N. Straetmans, B. Van Camp, and I. Van Riet, “Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3,” British Journal of Cancer, vol. 88, no. 6, pp. 855–862, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Salcedo, M. L. Ponce, H. A. Young et al., “Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression,” Blood, vol. 96, no. 1, pp. 34–40, 2000. View at Google Scholar · View at Scopus
  12. International Myeloma Working Group, “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group,” British Journal of Haematology, vol. 121, no. 5, pp. 749–757, 2003. View at Google Scholar
  13. E. Babarović, T. Valković, S. Štifter et al., “Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma,” American Journal of Clinical Pathology, vol. 137, no. 6, pp. 870–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Valković, E. Babarović, K. Lučin et al., “Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma,” BioMed Research International, vol. 2014, Article ID 513170, 6 pages, 2014. View at Publisher · View at Google Scholar
  15. A. Vacca, D. Ribatti, L. Roncali et al., “Bone marrow angiogenesis and progression in multiple myeloma,” British Journal of Haematology, vol. 87, no. 3, pp. 503–508, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. S. V. Rajkumar, R. A. Mesa, R. Fonseca et al., “Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis,” Clinical Cancer Research, vol. 8, no. 7, pp. 2210–2216, 2002. View at Google Scholar · View at Scopus
  17. S. V. Rajkumar, T. Leong, P. A. Roche et al., “Prognostic value of bone marrow angiogenesis in multiple myeloma,” Clinical Cancer Research, vol. 6, pp. 3111–3116, 2000. View at Google Scholar
  18. O. Sezer, K. Niemöller, J. Eucker et al., “Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma,” Annals of Hematology, vol. 79, no. 10, pp. 574–577, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. N. C. Munshi and C. Wilson, “Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis,” Seminars in Oncology, vol. 28, no. 6, pp. 565–569, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Schreiber, J. Ackermann, A. Obermair et al., “Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization,” British Journal of Haematology, vol. 110, no. 3, pp. 605–609, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Sezer, K. Niemöller, C. Jakob et al., “Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma,” Annals of Hematology, vol. 80, no. 10, pp. 598–601, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Niu, A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy, “Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP),” Journal of Biological Chemistry, vol. 283, no. 21, pp. 14542–14551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Rana, S. Sharma, V. Agrawal, and U. Singh, “Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors,” Annals of Hematology, vol. 89, no. 8, pp. 789–794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. S. Bhatti, L. Kumar, A. K. Dinda, and R. Dawar, “Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters,” American Journal of Hematology, vol. 81, no. 9, pp. 649–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. K. Tzenou, G. Levidou, N. Kavantzas et al., “Increased bone marrow total vascular area (TVA) correlates with a more aggressive disease in Waldenström's macroglobulinemia (WM) patients,” Haematologica, vol. 97, supplement 1, abstract 1534, 2012. View at Google Scholar
  26. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Chen and D. V. Goeddel, “TNF-R1 signaling: a beautiful pathway,” Science, vol. 296, no. 5573, pp. 1634–1635, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Lichtenstein, J. Berenson, D. Norman, M.-P. Chang, and A. Carlile, “Production of cytokines by bone marrow cells obtained from patients with multiple myeloma,” Blood, vol. 74, no. 4, pp. 1266–1273, 1989. View at Google Scholar · View at Scopus
  29. M. G. Alexandrakis, F. H. Passam, A. Sfiridaki, E. Kandidaki, P. Roussou, and D. S. Kyriakou, “Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity,” American Journal of Hematology, vol. 72, no. 4, pp. 229–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Lee, J.-I. Oh, J. Park et al., “TNFα mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells,” BioMed Research International, vol. 2013, Article ID 580135, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. B. K. Arendt, A. Velazquez-Dones, R. C. Tschumper et al., “Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells,” Leukemia, vol. 16, no. 10, pp. 2142–2147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Johrer, K. Janke, J. Krugmann, M. Fiegel, and R. Greil, “Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1,” Clinical Cancer Research, no. 15, pp. 1901–1910, 2004. View at Google Scholar
  33. Z. Liu, J. Xu, H. Li et al., “Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression,” PLoS ONE, vol. 8, no. 12, Article ID e82453, 2013. View at Publisher · View at Google Scholar · View at Scopus